Engineering bacterium for cysteine depletion and application of engineering bacterium in preparation of medicine for treating tumor ferroptosis

By colonizing and releasing engineered bacteria of cystsulfide γ-lyase at the tumor site, blocking the cysteine ​​metabolism pathway of tumor cells, the problems of low tumor targeting efficiency and toxic side effects in the prior art are solved, and the problem of low tumor targeting efficiency and toxic side effects are achieved. Effective treatment of a variety of cancers.

CN118879604APending Publication Date: 2024-11-01XIDIAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411086544.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-08
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The existing ferrodemortized nanodelivery systems are not efficient in tumor targeting and have toxic side effects on normal tissues, making it difficult to completely block the cysteine ​​metabolism pathway of tumor cells, resulting in limited therapeutic effects.

Method used

Design an engineered bacteria for cysteine ​​depletion, by introducing bacteria that encode genes of cystsulfide γ-lyase, utilizing its hypoxic tendency and tumor invasiveness to stabilize colonize and continuously release cystsulfide at the tumor site. γ-lyase blocks the cysteine ​​metabolism pathway of tumor cells, and combines biofilm engineering modification to improve targeting and anti-phagocytosis.

Benefits of technology

The precise regulation of the cysteine ​​metabolism pathway in the tumor site has been achieved, the tumor targeting and treatment effect has been improved, the toxic side effects on normal tissues have been reduced, and the treatment effect of a variety of cancers has been significantly improved.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879604A_ABST
    Figure CN118879604A_ABST
Patent Text Reader

Abstract

The invention relates to an engineering bacterium for cysteine depletion and application of the engineering bacterium in preparation of a medicine for treating tumor ferroptosis, and belongs to the technical field of biological medicines. The invention provides an engineering bacterium for cysteine depletion. The engineering bacterium comprises a chassis bacterial cell and an exogenous gene introduced into the chassis bacterial cell, wherein the exogenous gene enables the engineering bacteria to express cystathionine gamma-lyase. The invention also provides application of the engineering bacterium in preparation of biological agents for treating tumor diseases. The tumor disease is one of triple negative breast cancer, lung cancer, pancreatic cancer, gastric cancer or ovarian cancer. According to the engineering bacterium, cysteine at tumor tissue is specifically exhausted, operation of a ferroptosis defensive system is completely blocked, efficient ferroptosis treatment is expected to be achieved, and the engineering bacterium can be used for treating ferroptosis in order to improve the tumor enrichment efficiency of metabolic engineering bacteria and maximize the metabolism regulation function. The engineering bacteria are subjected to surface modification by utilizing a multifunctional fusion biological membrane with long-acting circulation and tumor targeting.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and specifically relates to an engineered bacterium for cysteine ​​depletion and an application thereof in the preparation of a drug for treating tumor ferroptosis. Background Art

[0002] Ferroptosis is a special form of programmed cell death that is iron-dependent and lipid peroxidation-driven. After more than a decade of uninterrupted research by researchers, it has been found that ferroptosis design has a broad biological background and plays an important role in many physiological and pathological processes such as development, aging, immunity, and tumors. It can also be applied to the field of tumor treatment. Compared with normal tissue cells, cancerous cells have sufficient prerequisites for ferroptosis due to the reconstruction of metabolic networks (lipid anabolism, redox metabolism, and iron homeostasis metabolism) caused by tumor metabolic reprogramming. Therefore, ferroptosis has attracted much attention and favor from researchers as a new therapeutic strategy targeting tumor metabolic vulnerability. In addition, unlike cell apoptosis caused by traditional chemotherapy, ferroptosis can effectively avoid primary and secondary apoptosis tolerance of tumor cells, thereby overcoming the chemotherapy resistance of tumors. Therefore, compared with traditional chemotherapy, ferroptosis therapy has better tumor selectivity and therapeutic performance, and is expected to become an ideal means of targeted tumor therapy.

[0003] Ferroptosis is caused by lipid peroxidation due to the accumulation of ROS. When the production of lipid peroxides on the biomembrane exceeds the ability of the ferroptosis defense system to resist, it will cause the accumulation of lipid peroxides and thus induce ferroptosis. Based on this, the current treatment strategy for tumor ferroptosis is often to accelerate the production of lipid peroxides and inhibit the operation of the tumor ferroptosis defense system through a combined synergistic effect, that is, to use iron-based nanocarriers to carry small molecule inhibitory drugs of the ferroptosis defense system. On the one hand, the iron ions in the iron-based nanomaterials will positively induce the occurrence of ferroptosis through the Fenton reaction, and on the other hand, the small molecule inhibitory drugs carried can reduce the ability of tumor cells to resist ferroptosis, ultimately producing a synergistic effect to efficiently induce ferroptosis.

[0004] However, the ferroptosis defense system inhibitory drugs currently used mostly target the GPX4-GSH resistance system, with a single target, but tumors have built a very complete defense system during their development. In addition to the GPX4 pathway, there are currently three other mechanisms involved in ferroptosis regulation: the FSP1 / CoQ10 / NADPH pathway, the DHODH pathway, and the GCH1 / BH4 pathway. Multiple ferroptosis defense pathways compensate for each other, making it difficult to completely and efficiently block the ferroptosis resistance of the ferroptosis defense system, resulting in existing related research still facing huge challenges in clinical transformation and application.

[0005] Through a systematic and comprehensive analysis of the metabolic regulatory network of the tumor ferroptosis defense system, it was found that the sulfur-containing complex acid cysteine ​​metabolic pathway is the metabolic center of some tumors' resistance to ferroptosis. The current tumor cell defense system against ferroptosis mainly relies on the reducing substrates GSH and CoQ10 to neutralize oxidative lipid peroxides, and cysteine, as the synthetic substrate of GSH and CoQ10, is the main driving force for the operation of the ferroptosis defense system.

[0006] At present, the regulatory strategies for cysteine ​​metabolism mainly include: dietary intervention to deprive cysteine, ferroptosis defense system inhibitory drugs such as Erastin, and ferroptosis nanodelivery systems. However, the dietary intervention regulatory strategy is limited to patients with advanced colorectal cancer (CRC). It has poor operability for patients with other types of cancer, low patient compliance, and slow onset of effect. Erastin and other single action pathways still cannot completely block the depletion of cysteine. The existing ferroptosis nanodelivery system has low tumor targeting efficiency and still has toxic side effects on normal tissues.

[0007] Therefore, there is an urgent need to develop a more effective and comprehensive approach to interrupt the ferroptosis defense mechanism. Summary of the invention

[0008] In view of the defects existing in the above-mentioned prior art, in order to solve the problem that the tumor targeting efficiency of the ferroptosis nano-delivery system is not high and there are still toxic side effects on normal tissues, the purpose of the present invention is to design and provide an engineered bacterium for cysteine ​​depletion, a preparation method and its application in the preparation of drugs for treating tumor ferroptosis. The engineered bacteria provided by the present invention have tumor targeting, can stably colonize at the tumor site and continuously release cystathionine γ-lyase, thereby completely blocking the operation of the ferroptosis defense system.

[0009] In order to achieve the above object, the present invention adopts the following technical solutions:

[0010] The first aspect of the present invention provides an engineered bacterium for cysteine ​​depletion, the engineered bacterium comprising a chassis bacterial cell and an exogenous gene introduced into the chassis bacterial cell;

[0011] Wherein, the chassis bacterial cells include at least one of attenuated Salmonella typhimurium VNP20009, Escherichia coli Nissle1917 and Escherichia coli MG1655;

[0012] The introduced exogenous gene enables the engineered bacteria to express cystathionine γ-lyase.

[0013] The exogenous gene comprises a cystathionine γ-lyase encoding gene, a promoter and a signal peptide; preferably, the promoter is a hypoxic promoter; preferably, the hypoxic promoter is a pPepT constitutive hypoxic promoter, and the nucleotide sequence of the pPepT constitutive hypoxic promoter is shown in SEQ ID NO.1; preferably, the signal peptide is at least one of PelB, OmpA or L-AsPsII, wherein the nucleotide sequence of the signal peptide PelB is shown in SEQ ID NO.2; the amino acid sequence of the signal peptide OmpA is shown in SEQID NO.6; the amino acid sequence of the signal peptide L-AsPsII is shown in SEQ ID NO.7.

[0014] The exogenous gene contains an expression vector; preferably, the expression vector is one of pBR322, pQE-30 or pET-28(a).

[0015] The exogenous gene further comprises a purification tag; preferably, the purification tag is at least one of HIS, HIS Tag, GST Tag or STag.

[0016] The amino acid sequence of the cystathionine γ-lyase is shown in SEQ ID NO.5.

[0017] The nucleotide sequence of the gene encoding cystathionine γ-lyase is shown in SEQ ID NO.3.

[0018] The engineered bacteria also include biomembrane engineering modification. Preferably, at least one or a mixed membrane of tumor cell membrane, erythrocyte membrane, and macrophage membrane can be used to modify the engineered bacteria. Any commonly used envelope modification method in the art can be applied to the present invention, for example, extrusion method can be used. Biomembrane engineering modification can make the engineered bacteria more adaptable to the needs of different application scenarios. For example, modification with tumor cell membrane can further improve the targeting ability of the engineered bacteria; modification with macrophage membrane can enhance the anti-phagocytic ability of the engineered bacteria; modification with erythrocyte membrane can improve the long-term circulation ability of the engineered bacteria.

[0019] The second aspect of the present invention provides the use of the engineered bacteria described in the first aspect in the preparation of a biological agent for treating a tumor disease; preferably, the tumor disease is selected from one of triple-negative breast cancer, lung cancer, pancreatic cancer, gastric cancer or ovarian cancer; preferably, the type of the tumor is one of a primary tumor, a postoperative recurrent tumor or a metastatic tumor.

[0020] The third aspect of the present invention provides a biological preparation for treating tumor diseases, the biological preparation comprising the engineered bacteria and an anticancer drug. Preferably, the anticancer drug is an immune checkpoint inhibitor drug; more preferably, the immune checkpoint inhibitor drug is a PD-L1 antibody.

[0021] Through the above technical solution, the present invention can at least achieve the following beneficial effects:

[0022] (1) The present invention uses "live bacteria" as delivery vectors, taking advantage of the bacteria's autonomous hypoxia tropism ability and tumor invasion, penetration and colonization capabilities to achieve efficient enrichment at the tumor site.

[0023] (2) The engineered bacteria provided by the present invention can target the tumor site and continuously release cystathionine γ-lyase at the target site, deplete cysteine ​​in the tumor microenvironment, accurately regulate cysteine ​​metabolism in the tumor site, and achieve blocking of the cysteine ​​metabolic pathway in the tumor.

[0024] (3) The engineered bacteria provided by the present invention have improved tumor targeting and / or anti-phagocytosis and / or long-term circulation capabilities based on biofilm engineering modification, building an application platform suitable for the treatment of different tumors, significantly improving the therapeutic effects on a variety of different cancers, and have high potential clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 is the plasmid map of the plasmid pBR322-pPept-PelB-CGL-HIS constructed in Example 1;

[0026] Figure 2 The PCR results of the plasmid pBR322-pPept-PelB-CGL-HIS and the corresponding cysteine ​​metabolism regulation engineering bacteria in Example 2;

[0027] Figure 3 This is the Elisa quantitative graph of CGL production by cysteine ​​metabolism regulation engineering bacteria under different oxygen gradient induction in Example 3;

[0028] Figure 4 The enzyme kinetics of the CGL enzyme catalyzing the decomposition of cystine and cysteine ​​based on the Michaelis-Menten equation in Example 3;

[0029] Figure 5 is the relative cysteine ​​concentration of tumor tissue at different treatment time points in Example 4;

[0030] Figure 6 The scanning electron microscopy and transmission electron microscopy images of the multifunctional biofilm engineered modified engineered bacteria in Example 5;

[0031] Figure 7 This is a confocal fluorescence image of the multifunctional biofilm engineered modified engineered bacteria in Example 5;

[0032] Figure 8The flow cytometry results of the incubation of the multifunctional biofilm engineered bacteria with macrophages / tumor cells in Example 5, wherein a represents the immune escape performance of the engineered bacteria, and b represents the tumor targeting performance of the engineered bacteria;

[0033] Fig. 9 This is a graph showing the in vivo targeted enrichment effect test results of the multifunctional biofilm engineered modified engineered bacteria in Example 6;

[0034] Fig.10 This is a graph showing the tumor volume of mice using the multifunctional biofilm engineered bacteria in the TNBC orthotopic model in Example 7;

[0035] Fig.11 This is a fluorescence quantitative image of mouse tumors in the TNBC metastasis model using multifunctional biofilm engineered bacteria combined with immunotherapy in Example 8;

[0036] Fig.12 This is a graph showing the tumor volume of mice treated with multifunctional biofilm engineered bacteria combined with immunotherapy for postoperative recurrent TNBC in Example 9;

[0037] Fig.13 This is the survival curve of mice using biofilm engineered bacteria for lung cancer treatment in Example 10;

[0038] Fig.14 This is the tumor growth curve of mice using the multifunctional biofilm engineered bacteria in Example 11 for the treatment of pancreatic cancer. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments and the accompanying drawings.

[0040] Example 1: Construction of recombinant plasmid

[0041] 1.1 Construction of target gene sequence

[0042] (1) Construction of pPept-PelB-CGL-HIS sequence

[0043] The gene sequences of CGL enzyme and signal peptide PelB were optimized and synthesized, the gene sequences of the screened hypoxia sensing element pPept (nucleotide sequence as shown in SEQ ID NO.1), signal peptide PelB (nucleotide sequence as shown in SEQ ID NO.2), gene encoding CGL enzyme (nucleotide sequence as shown in SEQ ID NO.3), and tag HIS (nucleotide sequence as shown in SEQ ID NO.4) were spliced ​​through the high-efficiency cloning plasmid pMD-18T, and transformed into the plasmid recipient bacteria DH5α to obtain the recombinant cloning bacteria pMD-18T-pPept-PelB-CGL-HIS-DH5α, PCR primers of the target sequence (pPept-PelB-CGL-HIS) were designed, and a full-length PCR synthesis reaction was carried out to obtain the full-length sequence of the target gene containing the restriction site, and the pPept-Pel B-CGL-HIS gene fragment was recovered.

[0044] (2) Construction of pPept-OmpA-CGL-HIS sequence

[0045] The construction method is the same as 1.1 (1), except that the signal peptide is replaced with OmpA (amino acid sequence as shown in SEQ ID NO. 6), and the pPept-OmpA-CGL-HIS gene fragment is recovered.

[0046] (3) Construction of pPept-L-AsPsII-CGL-HIS sequence

[0047] The construction method is the same as 1.1 (1), except that the signal peptide is replaced with L-AsPsII (amino acid sequence as shown in SEQ ID NO.7), and the pPept-L-AsPsII-CGL-HIS gene fragment is recovered.

[0048] 1.2 Synthesis of recombinant plasmid

[0049] (1) Using the expression vector pBR322 as the gene chassis, the target sequence was connected to the expression plasmid pBR322 using double restriction enzyme ligation technology, and a single clone colony was selected for gene identification to obtain a DH5α strain containing the recombinant plasmid pBR322-pPept-PelB-CGL-HIS. Figure 1 This is the plasmid map of the recombinant plasmid pBR322-pPept-PelB-CGL-HIS.

[0050] (2) Using the expression vector pQE-30 as the gene chassis, the construction method was the same as 1.2(1) to obtain a DH5α strain containing the recombinant plasmid pQE-30-pPept-OmpA-CGL-HIS.

[0051] (3) Using the expression vector pET-28(a) as the gene chassis, the construction method was the same as 1.2(1) to obtain a DH5α strain containing the recombinant plasmid pET-28(a)-pPept-L-AsPsII-CGL-HIS.

[0052] The recombinant plasmids pBR322-pPept-PelB-CGL-HIS, pQE-30-pPept-OmpA-CGL-HIS, and pET-28(a)-pPept-L-AsPsII-CGL-HIS were extracted from different recombinant bacteria using an endotoxin-free plasmid mini-extraction kit (Tiangen Biochemical Technology Co., Ltd.).

[0053] Example 2: Construction of cysteine ​​metabolic engineering bacteria

[0054] 2.1 Construction of engineered bacteria using attenuated Salmonella VNP20009 as the chassis.

[0055] The extracted recombinant plasmid pBR322-pPept-PelB-CGL-HIS was introduced into VNP20009 competent cells by electroporation, and then spread on LB plates containing 50 mg / L ampicillin. After overnight culture at 37°C, positive colonies were identified by PCR, restriction digestion and sequencing. Figure 2 These are the PCR results for plasmid pBR322-pPept-PelB-CGL-HIS and the corresponding cysteine ​​metabolism regulation engineered bacteria. The target fragment size is about 2100 bp. There is no target band without adding the primer set. The primer + plasmid set has an obvious band at 2100 bp, proving that the plasmid was successfully constructed. The band appears in the primer + bacteria set, proving that the engineered bacteria were successfully constructed. The obtained positive clone strain is the engineered bacteria VNP-pBR322-pPept-PelB-CGL-HIS.

[0056] 2.2 Construction of engineered bacteria using Escherichia coli Nissle1917 as the chassis.

[0057] The construction method is the same as 2.1, except that the competent cells are replaced with competent cells of E. coli Nissle1917, and the recombinant plasmid in 1.2 (2) is used to obtain the engineered bacteria Nissle-pQE-30-pPept-OmpA-CGL-HIS.

[0058] 2.3 Construction of engineered bacteria using Escherichia coli Mg1655 as the chassis.

[0059] The construction method is the same as 2.1, except that the competent cells are replaced with competent cells of E. coli Mg1655, and the recombinant plasmid constructed in 1.2(3) is introduced by thermal transformation to obtain the engineered bacteria Mg1655-pET-28(a)-pPept-L-AsPsII-CGL-HIS.

[0060] Example 3: Functional verification of engineered bacteria

[0061] 1. Hypoxia response ability

[0062] The anaerobic response ability of the engineered bacteria was evaluated by ELISA experiment: the engineered bacteria VNP-pBR322-pPept-PelB-CGL-HIS obtained in Example 2 was induced for 12 h under different oxygen concentration gradients, and the samples were treated with Ripa lysis solution and the efficiency of producing CGL enzyme in response to anaerobic reaction was qualitatively analyzed by ELISA kit (Jianglai Biotechnology).

[0063] The results are as follows Figure 3 As shown in the figure, it can be seen that as the oxygen content decreases, the CGL expression level of the engineered bacteria gradually increases.

[0064] 2. Functional test of expressed CGL enzyme

[0065] The engineered bacteria VNP-pBR322-pPept-PelB-CGL-HIS was induced under hypoxic conditions for 12 h. The enzyme kinetics of CGL enzyme catalyzing the decomposition of cystine and cysteine ​​was calculated based on the Michaelis-Menten equation by using the method of detecting the substrate pyruvate using a pyruvate detection kit. The results are as follows Figure 4 As shown in the figure, it can be seen that the engineered bacteria can effectively degrade kynurenine under hypoxic induction conditions.

[0066] The same method was used to test and verify the functions of the engineered bacteria Nissle-pQE-30-pPept-OmpA-CGL-HIS and Mg1655-pET-28(a)-pPept-L-AsPsII-CGL-HIS, and similar test results were obtained, indicating that the engineered bacteria constructed in Example 2 all have the ability to express CGL enzymes in the tumor site (hypoxic environment) and decompose cystine and cysteine, while basically do not express CGL enzymes in normal tissues, and have the potential to be used for targeted depletion of cysteine ​​in the tumor microenvironment.

[0067] Example 4: In vivo evaluation of the cysteine ​​regulation performance of engineered bacteria

[0068] The tumors were in good condition and of the same size (75 mm 3The TNBC orthotopic tumor model mice were randomly divided into 3 groups and given PBS (100 μL), CGL (0.2 mg dispersed in 100 μL PBS), ZZY (VNP-pBR322-pPepT-PelB-CGL-HIS was denoted as ZZY, 10 7 CFU ZZY was dispersed in 100 μL PBS); all treatment groups were injected intratumorally. The cysteine ​​content in tumor tissue at different time points was measured using a cysteine ​​detection kit to monitor the consumption of cysteine. The monitoring time points were 12h, 24h, 48h, and 72h. The mice at the above time points were killed, and the tumor tissues were collected. After grinding and homogenization, the supernatant was collected for cysteine ​​quantification. The results are shown in Figure 5 As shown in the figure, after 12 hours of intratumoral administration, the cysteine ​​clearance effect of the CGL group was better than that of ZZY, but the effects of the two groups were the same at 24 hours. However, over time, the cysteine ​​level in the tumor tissue treated with CGL gradually recovered, while the cysteine ​​level in the tumor tissue treated with ZZY remained low, indicating that the engineered bacteria ZZY can continuously and effectively consume cysteine, thereby inhibiting cysteine ​​metabolism.

[0069] Example 5: Multifunctional biofilm engineering modified bacteria

[0070] This example is used to illustrate the method for engineering modification of engineered bacterial biofilm provided by the present invention and its modification effect. The biofilm includes erythrocyte membrane, tumor cell membrane, macrophage membrane, etc. or a hybrid membrane, such as a hybrid of erythrocyte and macrophage.

[0071] In order to further improve the targeting and anti-phagocytic ability of the engineered bacteria, the in situ tumor cell membrane and macrophage membrane of the in situ TNBC mouse model were used to encapsulate the engineered bacteria VNP-pBR322-pPepT-PelB-CGL-HIS obtained in Example 2 (using the thin film extrusion method, that is, the macrophage membrane and the tumor cell membrane were evenly mixed and then co-extruded with the engineered bacteria for modification). The obtained engineered bacteria was recorded as ZZY@MT (M: macrophage membrane, T: tumor cell membrane).

[0072] The coating and modification of the biofilm were directly observed by SEM and TEM. The results are shown in Figure 6 . Figure 6 It shows that compared with the unmodified ZZY, the morphology of ZZY@MT will not change due to the modification of the multifunctional biomembrane. Using TEM and SEM to analyze the morphology, structure and other information of ZZY@MT and ZZY, it can be clearly found that the outside of ZZY@MT is covered with a lipid bilayer membrane structure.

[0073] The engineered bacteria were labeled with green fluorescent protein GFP, and the multifunctional fusion membrane was labeled with Anti-CD47. The staining results were analyzed by confocal microscopy. The results are detailed in Figure 7 . Figure 7 The dye merging of the engineered bacteria ZZY@MT was shown to be good, proving that the macrophage membrane and triple-negative breast cancer membrane were well mixed and successfully modified on the surface of the engineered bacteria.

[0074] Subsequently, the cells were characterized at the cellular level by culturing macrophages and tumor cells in confocal microplates, incubating GFP-labeled engineered bacteria ZZY@MT or ZZY, and characterizing them using flow cytometry. The results are detailed in Figure 8 . Figure 8 It was shown that the engineered bacteria modified with multifunctional biofilm exhibited excellent immune escape and tumor targeting properties.

[0075] In order to further improve the long-term circulation ability of the engineered bacteria, the extracted red blood cell membrane was used to perform envelope modification on the engineered bacteria VNP-pBR322-pPepT-PelB-CGL-HIS obtained in Example 2 (using the thin film extrusion method, that is, the red blood cell membrane and the engineered bacteria were co-extruded for modification), and the obtained engineered bacteria can be recorded as ZZY@R (R: red blood cell membrane).

[0076] In order to further improve the long-term circulation ability and anti-phagocytic ability of the engineered bacteria, the engineered bacteria ZZY obtained in Example 2 were enveloped and modified using the extracted red blood cell membrane and macrophage membrane (using the thin film extrusion method, that is, the red blood cell membrane and the macrophage membrane were evenly mixed and then co-extruded with the engineering bacteria for modification). The obtained engineered bacteria can be recorded as ZZY@RM (R: red blood cell membrane, M: macrophage membrane).

[0077] Those skilled in the art can select the desired biofilm modification material according to actual needs, so it will not be described in detail.

[0078] The same method was used to test and verify the modification effects of the engineered bacteria ZZY@R and ZZY@RM, and similar test results were obtained, indicating that the selected target biofilm was well modified on the surface of the engineered bacteria and had corresponding properties.

[0079] Example 6: Evaluation of the in vivo targeted enrichment effect of engineered bacteria

[0080] The tumors were in good condition and of the same size (75 mm 3 The TNBC orthotopic tumor model mice were randomly divided into 4 groups: ZZY, ZZY@M (macrophage membrane modification), ZZY@T (TNBC tumor cell membrane modification), and ZZY@MT. 7CFU of engineered bacteria. All mice were killed and analyzed at the specified time points (1 mouse each at 12h, 24h, 48h, and 72h). The heart, liver, spleen, lung, kidney, brain, and tumor tissues of the mice were homogenized in a glass homogenizer. Serial dilutions were made with LB medium, and 50 μL of the dilutions were added to LB-Amp agar plates with antibiotics. Incubated overnight at 37°C, the bacteria were counted and the engineered bacteria content per gram of tissue was calculated. For details of the colony count results of the 72h tumor tissue bacterial plate, see Fig. 9 . Fig. 9 It can be seen that bacteria coated with mixed cell membranes are more enriched in tumors, proving that bacteria coated with mixed membranes have better targeting performance.

[0081] The same method was used to test and verify the targeting of the engineered bacteria Nissle-pQE-30-pPept-OmpA-CGL-HIS and Mg1655-pET-28(a)-pPept-L-AsPsII-CGL-HIS, and similar test results were obtained, indicating that the engineered bacteria provided by the present invention have good tumor targeting and can be effectively colonized at the tumor site.

[0082] Example 7: Cysteine ​​metabolism regulation engineered bacteria for the treatment of TNBC

[0083] The tumors were in good condition and of the same size (75 mm 3 The TNBC orthotopic model mice were randomly divided into four groups: (1) PBS group: 100 μL PBS was injected into the tail vein at the beginning of treatment; (2) WT@MT group (wild VNP20009 type modified with hybrid membrane of macrophages and TNBC tumor cells): 10 7 CFU engineered bacteria: (3) ZZY@MT group (engineered bacteria modified with hybrid membrane of macrophages and TNBC tumor cells): treatment started with tail vein injection for 10 7 CFU engineered bacteria; (4) ZZY@MT+DFO group: treatment started with tail vein injection for 10 7 CFU engineered bacteria, and an appropriate amount of ferroptosis inhibitor DFO was injected intraperitoneally. The tumor growth of tumor-bearing mice in each group during the treatment period is shown in Fig.10 As shown, it can be seen that the ZZY@MT group showed a good inhibitory effect on triple-negative breast cancer.

[0084] Example 8: Cysteine ​​metabolism regulation engineered bacteria for combined immunotherapy in TNBC metastasis model

[0085] 4T1-luc cells (4T1 mouse breast cancer cells with luciferase label) were grown in RPMI-1640 cell culture medium until the exponential growth phase and then digested with 0.5% trypsin. The cells were then centrifuged at 800 rpm for 5 min. The supernatant was removed and washed twice with PBS. The cells were counted and 100 μL of cell suspension was slowly injected into the tail vein of each mouse, i.e., 2×10 5 After inoculation, the mice were housed in a clean animal room, and the tumor growth was monitored and treated using an IVIS imaging system.

[0086] The mice were randomly divided into four groups: (1) PBS group: 100 μL PBS was injected into the tail vein at the beginning of treatment; (2) PD-L1 group: PD-L1 solution (12.5 mg / kg) was injected intraperitoneally every three days at the beginning of treatment; (3) ZZY@MT group (ZZY@MT: engineered bacteria modified with hybrid membrane of macrophages and TNBC tumor cells): 10 7 CFU engineered bacteria; (4) ZZY@MT+PD-L1 group (ZZY@MT: engineered bacteria modified with hybrid membranes of macrophages and TNBC tumor cells): treatment started with tail vein injection for 10 7 CFU engineered bacteria, and PD-L1 solution (12.5 mg / kg) was injected intraperitoneally every three days.

[0087] During the treatment period, the tumor growth of tumor-bearing mice in each group was characterized by IVIS. The results are shown in Fig.11 It can be seen that the engineered bacteria combined with immunotherapy group showed inhibition on metastatic triple-negative breast cancer.

[0088] Example 9: Cysteine ​​metabolism-regulated engineered bacteria for combined immunotherapy of postoperative recurrent TNBC

[0089] To simulate the residual recurrence after clinical TNBC surgery, a tumor was formed in situ in the left breast, which was recorded as the primary tumor. 3 The mice were randomly divided into four groups: (1) PBS group: 100 μL PBS was injected into the tail vein at the beginning of treatment; (2) PD-L1 group: PD-L1 solution (12.5 mg / kg) was injected intraperitoneally every three days at the beginning of treatment; (3) ZZY@MT group (ZZY@MT: engineered bacteria modified with hybrid membrane of macrophages and TNBC tumor cells): 10 7 CFU engineered bacteria; (4) ZZY@MT+PD-L1 group (ZZY@MT: engineered bacteria modified with hybrid membranes of macrophages and TNBC tumor cells): treatment started with tail vein injection for 10 7 CFU engineered bacteria, and PD-L1 solution (12.5 mg / kg) was injected intraperitoneally every three days.

[0090] The tumor growth of tumor-bearing mice in each group during the treatment period is shown in Figure 2. Fig.12 As shown, it can be seen that the engineered bacteria combined with immunotherapy group inhibited the recurrent triple-negative breast cancer and significantly improved the survival rate of mice.

[0091] Example 10: Biofilm-modified cysteine ​​metabolism-regulating engineered bacteria for the treatment of lung cancer

[0092] Lewis-luc cells (Lewis mouse lung cancer cells with luciferase label) were grown in DMEM cell culture medium to the exponential growth phase and then digested with 0.5% trypsin. The cells were then centrifuged at 800 rpm / min for 5 min. The supernatant was removed and washed twice with PBS. The cells were counted and 100 μL was inoculated into the lungs of each C57BL / 6 mouse, i.e., 5×10 6 After inoculation, the mice were housed in a clean animal room, and the tumor growth was monitored and treated using an IVIS imaging system.

[0093] The mice were randomly divided into 2 groups: (1) PBS group: 100L PBS was injected into the tail vein at the beginning of treatment; (2) engineered bacteria group (ZZY@T, engineered bacteria VNP-pBR322-pPepT-PelB-CGL-HIS modified with Lewis lung cancer cell membrane): engineered bacteria were injected intravenously for 10 8 CFU (in the exponential growth phase, dissolved in 100 μL PBS), the drug was administered twice, with an interval of 3 days; the mice were killed on the third day after the end of treatment, and the tumors of the tumor-bearing mice were taken out under a sterile environment, weighed and recorded.

[0094] The survival curves of tumor-bearing mice in each group during the treatment period are shown in Figure 2. Fig.13 As shown, it can be seen that the engineered bacteria group showed a good lung cancer inhibition effect.

[0095] Example 11: Multifunctional biofilm-modified cysteine ​​metabolism-regulating engineered bacteria for the treatment of pancreatic cancer

[0096] Panc02-luc cells (Panc02 mouse pancreatic ductal adenocarcinoma cells with luciferase label) were grown in RPMI-1640 cell culture medium until the exponential growth phase and then digested with 0.5% trypsin. The cells were then centrifuged at 800 rpm / min for 5 min. The supernatant was removed and washed twice with PBS. The cells were counted and 100 μL was inoculated into the pancreas of each C57BL / 6 mouse, i.e., 5×10 6After inoculation, the mice were housed in a clean animal room. After inoculation, the mice were housed in a clean animal room, and tumor growth was monitored and treated using an IVIS imaging system. The mice were randomly divided into 2 groups: (1) PBS group: 100L PBS was injected into the tail vein at the beginning of treatment; (2) engineered bacteria group (ZZY@RT, engineered bacteria VNP-pBR322-pPepT-PelB-KYNase modified with hybrid membranes of red blood cells and Panc02 pancreatic ductal adenocarcinoma cells): the engineered bacteria were injected intravenously for 10 8 CFU (in the exponential growth phase, dissolved in 100 μL PBS), administered twice with an interval of 3 days.

[0097] The tumor growth of pancreatic cancer mice was characterized by IVIS. Fig.14 As shown. It can be seen that the engineered bacteria group showed a good pancreatic cancer inhibitory effect.

Claims

1. An engineered bacterium for cysteine ​​depletion, characterized in that: The engineered bacteria include chassis bacterial cells and foreign genes introduced into the chassis bacterial cells; Among them, the exogenous gene enables the engineered bacteria to express cystathionine γ-lyase.

2. An engineered bacterium for cysteine ​​depletion according to claim 1, characterized in that: The chassis bacterial cells are selected from at least one of attenuated Salmonella typhimurium VNP20009, Escherichia coli Nissle1917 or Escherichia coli MG1655.

3. An engineered bacterium for cysteine ​​depletion according to claim 1, characterized in that: The exogenous gene comprises a cystathionine γ-lyase encoding gene, a promoter and a signal peptide; Preferably, the promoter is a hypoxic promoter; Preferably, the hypoxic promoter is a pPepT constitutive hypoxic promoter, and the nucleotide sequence of the pPepT constitutive hypoxic promoter is shown in SEQ ID NO.1; Preferably, the signal peptide is at least one of PelB, OmpA or L-AsPsII, wherein the nucleotide sequence of the signal peptide PelB is shown as SEQ ID NO.2; the amino acid sequence of the signal peptide OmpA is shown as SEQ ID NO.6; and the amino acid sequence of the signal peptide L-AsPsII is shown as SEQ ID NO.

7.

4. The engineered bacteria for cysteine ​​depletion according to claim 1, characterized in that: The exogenous gene contains an expression vector; Preferably, the expression vector is one of pBR322, pQE-30 or pET-28(a).

5. The engineered bacteria for cysteine ​​depletion according to claim 1, characterized in that: The exogenous gene also includes a purification tag; Preferably, the purification tag is at least one of HIS, HIS Tag, GST Tag or S Tag.

6. The engineered bacteria for cysteine ​​depletion according to claim 1, characterized in that: The amino acid sequence of the cystathionine γ-lyase is shown in SEQ ID NO.

5.

7. The engineered bacteria for cysteine ​​depletion according to claim 1, characterized in that: The nucleotide sequence of the gene encoding cystathionine γ-lyase is shown in SEQ ID NO.

3.

8. The engineered bacteria for cysteine ​​depletion according to claim 1 comprises biofilm engineering modification; Preferably, the biological membrane is a tumor cell membrane, an erythrocyte membrane or a macrophage membrane, or a mixed membrane of both.

9. Use of the engineered bacteria for cysteine ​​depletion according to any one of claims 1 to 8 in the preparation of biological agents for treating tumor diseases; Preferably, the tumor disease is selected from one of triple-negative breast cancer, lung cancer, pancreatic cancer, gastric cancer or ovarian cancer; Preferably, the type of the tumor disease is one of a primary tumor, a postoperative recurrent tumor or a metastatic tumor.

10. A biological agent for treating tumor diseases, characterized in that: The biological preparation comprises the engineered bacteria as claimed in claim 1 and an anticancer drug; Preferably, the anticancer drug is an immune checkpoint inhibitor drug; More preferably, the immune checkpoint inhibitor drug is a PD-L1 antibody.